{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:37:05Z","timestamp":1791308225793,"version":"4.3.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,12,12]],"date-time":"2014-12-12T00:00:00Z","timestamp":1418342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2014,12,12]],"date-time":"2014-12-12T00:00:00Z","timestamp":1418342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2015,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Amatuximab is a chimeric monoclonal antibody that targets mesothelin, which is expressed in virtually all mesotheliomas and pancreatic adenocarcinomas. The objective of this study was to determine the dose-limiting toxicity and the maximum tolerated dose. Patients with mesothelioma, pancreatic adenocarcinoma or other mesothelin-positive solid tumors were eligible for this study. Amatuximab was administered weekly as an intravenous infusion in 4-week cycles at progressively increasing doses ranging from 50 to 200\u00a0mg\/m<jats:sup>2<\/jats:sup>. Seventeen patients received amatuximab. Two dose-limiting toxicities were observed: one at 50\u00a0mg\/m<jats:sup>2<\/jats:sup> and one at 200\u00a0mg\/m<jats:sup>2<\/jats:sup>; the maximum tolerated dose of this study was determined to be 200\u00a0mg\/m<jats:sup>2<\/jats:sup>. Of the 17 patients, 13 patients (76.5\u00a0%) experienced treatment-related adverse events. The most common adverse events were grade 1 fatigue (29.4\u00a0%) and pyrexia (23.5\u00a0%). The maximum serum concentration and area under the concentration curve values increased in an almost dose-proportional manner. Three patients had stable disease. Amatuximab was generally well tolerated at doses up to 200\u00a0mg\/m<jats:sup>2<\/jats:sup>. The pharmacokinetic profile of amatuximab in the Japanese population was similar to that seen in the United States population (Clinical Trials.gov Identifier: NCT01018784).<\/jats:p>","DOI":"10.1007\/s10637-014-0196-0","type":"journal-article","created":{"date-parts":[[2014,12,11]],"date-time":"2014-12-11T05:36:55Z","timestamp":1418276215000},"page":"380-388","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors"],"prefix":"10.1007","volume":"33","author":[{"given":"Yasuhito","family":"Fujisaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayasu","family":"Kurata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunio","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Tsurutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyasu","family":"Kaneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isamu","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Namiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chifumi","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,12,12]]},"reference":[{"key":"196_CR1","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1128\/MCB.20.8.2902-2906.2000","volume":"20","author":"TK Bera","year":"2000","unstructured":"Bera TK, Pastan I (2000) Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol 20:2902\u20132906","journal-title":"Mol Cell Biol"},{"key":"196_CR2","doi-asserted-by":"publisher","first-page":"9190","DOI":"10.1074\/jbc.M312372200","volume":"279","author":"A Rump","year":"2004","unstructured":"Rump A, Morikawa Y, Tanaka M et al (2004) Binding of ovarian cancer antigen CA125\/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 279:9190\u20139198","journal-title":"J Biol Chem"},{"key":"196_CR3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1476-4598-5-50","volume":"5","author":"JA Gubbels","year":"2006","unstructured":"Gubbels JA, Belisle J, Onda M et al (2006) Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer 5:50","journal-title":"Mol Cancer"},{"key":"196_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.canlet.2007.04.012","volume":"255","author":"L Bergan","year":"2007","unstructured":"Bergan L, Gross JA, Nevin B, Urban N, Scholler N (2007) Development and in vitro validation of anti-mesothelin biobodies that prevent CA125\/mesothelin-dependent cell attachment. Cancer Lett 255:263\u2013274","journal-title":"Cancer Lett"},{"key":"196_CR5","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/ijc.2910500308","volume":"50","author":"K Chang","year":"1992","unstructured":"Chang K, Pastan I, Willingham MC (1992) Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 50:373\u2013381","journal-title":"Int J Cancer"},{"key":"196_CR6","first-page":"3862","volume":"7","author":"P Argani","year":"2001","unstructured":"Argani P, Iacobuzio-Donahue C, Ryu B et al (2001) Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 7:3862\u20133868","journal-title":"Clin Cancer Res"},{"key":"196_CR7","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1309\/F1B64CL7H8VJKEAF","volume":"124","author":"R Hassan","year":"2005","unstructured":"Hassan R, Laszik ZG, Lerner M, Raffeld M, Postier R, Brackett D (2005) Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol 124:838\u2013845","journal-title":"Am J Clin Pathol"},{"key":"196_CR8","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/01.MP.0000056981.16578.C3","volume":"16","author":"NG Ord\u00f3\u00f1ez","year":"2003","unstructured":"Ord\u00f3\u00f1ez NG (2003) Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 16:192\u2013197","journal-title":"Mod Pathol"},{"key":"196_CR9","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/01.pai.00000141545.36485.d6","volume":"13","author":"R Hassan","year":"2005","unstructured":"Hassan R, Kreitman RJ, Pastan I, Willingham MC (2005) Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol 13:243\u2013247","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"196_CR10","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/00000478-200302000-00002","volume":"27","author":"M Miettinen","year":"2003","unstructured":"Miettinen M, Sarlomo-Rikala M (2003) Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Am J Surg Pathol 27:150\u2013158","journal-title":"Am J Surg Pathol"},{"key":"196_CR11","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1097\/00000478-200308000-00001","volume":"27","author":"NG Ord\u00f3\u00f1ez","year":"2003","unstructured":"Ord\u00f3\u00f1ez NG (2003) Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 27:1418\u20131428","journal-title":"Am J Surg Pathol"},{"key":"196_CR12","first-page":"20","volume":"7","author":"R Hassan","year":"2007","unstructured":"Hassan R, Ebel W, Routhier EL et al (2007) Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun 7:20","journal-title":"Cancer Immun"},{"key":"196_CR13","doi-asserted-by":"publisher","first-page":"6132","DOI":"10.1158\/1078-0432.CCR-10-2275","volume":"16","author":"R Hassan","year":"2010","unstructured":"Hassan R, Cohen SJ, Phillips M et al (2010) Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res 16:6132\u20136138","journal-title":"Clin Cancer Res"},{"key":"196_CR14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"196_CR15","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1002\/jps.20178","volume":"93","author":"ED Lobo","year":"2004","unstructured":"Lobo ED, Hansen RJ, Balthasar JP (2004) Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93:2645\u20132668","journal-title":"J Pharm Sci"},{"key":"196_CR16","unstructured":"Hassan R, Kindler HL, Jahan T, et al. (2014) Phase II clinical trial of amatuximab, a chimeric anti-mesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. http:\/\/clincancerres.aacrjournals.org\/content\/early\/2014\/09\/16\/1078-0432.CCR-14-0804.long. Accessed 5 November 2014"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-014-0196-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-014-0196-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-014-0196-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-014-0196-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:01:41Z","timestamp":1678510901000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-014-0196-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,12]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["196"],"URL":"https:\/\/doi.org\/10.1007\/s10637-014-0196-0","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,12]]},"assertion":[{"value":"11 October 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}